Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher's PPD clinical research business awarded 10-year Indefinite-Delivery, Indefinite-Quantity contract by National Cancer Institute

Thermo Fisher Scientific's PPD Clinical Research Business Selected to Support National Cancer Institute's Cancer Trials Support Unit

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific partners with the Taiwan Precision Medicine Initiative to support the large-scale predictive genomics study.

Thermo Fisher Scientific Collaborates with Taiwan Precision Medicine Initiative to Genotype 1 Million People in Taiwan

Thermo Fisher Scientific Inc. (NYSE:TMO ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 9:55 AM ET Company Participants Marc Casper - President & Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant All right, guys. Good morning.

Thermo Fisher Scientific Inc. (TMO) Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific has certified the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System* to meet new In Vitro Medical Devices Regulation (IVDR) requirements. The updated system now includes new, complementary Applied Biosystems Diomni Software ecosystem to empower clinical labs and test developers to leverage flexible PCR testing onsite. Designed for maximum productivity and fast ramp-up, the QuantStudio 7 Pro Dx Real-Time PCR System enables us

Thermo Fisher Scientific Certifies Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System to Meet IVDR Requirements

Bank of America

Disney

JPMorgan Chase & Co

Mastercard

NVIDIA

Pfizer

Tesla

Exxon Mobil

August started on a positive note, with the S&P 500 gaining over 5% in the first 10 days.

These Were The Five Best And Worst Performing Mega-Cap Stocks In August 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 2022 Global Healthcare Conference on Monday, September 12, 2022, at 9:55 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world l

Thermo Fisher Scientific to Present at Morgan Stanley 2022 Global Healthcare Conference

Thermo Fisher (TMO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is What to Know Beyond Why Thermo Fisher Scientific Inc. (TMO) is a Trending Stock

Thermo Fisher Scientific Inc. ( TMO , Financial) is a leading life sciences, diagnostics and laboratory products company. The company has worked to become customers' go-to name for life science products and consumables.

Thermo Fisher: A High Growth Health Care Name

Corning

There is more to the comparison, and in the sections below, we discuss why we believe TMO stock will offer better returns than GLW stock in the next three years.

This Company Is A Better Pick Over Corning Stock

CARLSBAD, Calif.--(BUSINESS WIRE)--Next-generation sequencing (NGS) is quickly becoming the platform of choice for tumor molecular profiling due to its ability to simultaneously report on multiple biomarkers. However, lengthy turnaround times can limit the clinical utility of these results. To meet the need for rapid genomic insights, Thermo Fisher Scientific today launched the CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx for use in clinical labs. Using targeted NGS technolog

Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing

MAASTRICHT, Netherlands--(BUSINESS WIRE)--The Thermo Scientific Orbitrap Ascend Tribrid offers new capabilities for multiplexed proteomics and native protein characterization.

Thermo Fisher Scientific Showcases Latest Innovations to Improve Biopharmaceutical and Proteomics Workflows

PerkinElmer

You've probably never heard of them, but they're both winners.

2 Ultra-Growth Stocks to Buy Hand Over Fist and Hold Forever

PLAINVILLE, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today expanded its cell and gene therapy capabilities with the opening of its new previously announced viral vector manufacturing facility in Plainville, Mass. The 300,000 square foot, state-of-the-art site will add approximately 300 jobs to support the development, testing and manufacture of viral vectors, which are critical components in the development and commercialization of gene therapies. “

Thermo Fisher Scientific Expands Viral Vector Manufacturing Capabilities

Chevron

Hasbro

Kimberly-Clark

Lamar Advertising

Microsoft

The safest blue-chip dividend stocks can be pretty easy to sort out. Investing in them makes sense in turbulent times like those we are currently experiencing.

The 7 Safest Blue-Chip Dividend Stocks to Buy for the Rest of 2022

Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.

Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today opened its largest single-use technology manufacturing site in Greater Nashville. The $105 million, 400,000-square-foot facility enables the company to help meet rapidly growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher's $650 million multi-year investment to expand its

Thermo Fisher Scientific's Largest Single-Use Technology Manufacturing Site Opens in Greater Nashville

These are profitable businesses that you can buy and hold for decades.

2 No-Brainer Buys During This Bear Market

Thermo Fisher has a very attractive product mix and market distribution. Strong performance across pharma, biotech, industrial, and diagnostics segments will continue well into the future.

Thermo Fisher: Strong Foundation For Growth

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.

Here's Why You Should Retain Thermo Fisher (TMO) Stock Now

Is Trending Stock Thermo Fisher Scientific Inc. (TMO) a Buy Now?

Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.

Thermo Fisher (TMO) Debuts Assay for Research on HIV Strains

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics. HIV RNA extracted from EDTA plasma or dried blood spots is analyzed with the assay to measure genomic mutations in the protease, reverse tra

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

American Tower

Cigna

Estee Lauder

Elevance Health Inc

ServiceNow

Prologis

S&P Global

Visa

Zoetis

Institutional investors are big investors that generally buy shares on behalf of their clients or members.

These Are The Ten Biggest Companies With Over 90% Institutional Ownership

Is Most-Watched Stock Thermo Fisher Scientific Inc. (TMO) Worth Betting on Now?

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support both DNA and RNA input, the Ion Torrent Oncomine Myeloid MRD Assays (RUO)* provide a comprehensive and highly sensitive MRD assessment from blood and bone marrow samples. Acute myeloid leukemia (AML) is characterized by rapid disease progression and can be fatal if not treated

News for Thermo Fisher Scientific Stock (TMO)